June 2011

CRANBURY, N.J., June 23, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that Alan W. Dunton, M.D., formally joined Palatin’s Board of Directors on June 22, 2011 as an independent director and member of Palatin’s Audit and Compensation Committees. “Dr. Dunton brings Palatin both substantial drug development experience and clinical research experience,” …

Alan Dunton, M.D., Joins Board of Directors of Palatin Technologies, Inc. Read More »

CRANBURY, N.J., June 21, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled “Amino Acid Surrogates for Peptidic Constructs.”  The claims in the issued patent cover a series of small molecule mimics for naturally occurring amino acids which can be …

Palatin Technologies, Inc. Issued U.S. Patent for Key Component in PL-3994 Drug Candidate Read More »

CRANBURY, N.J., June 15, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.  The underlying study was supported by grants from Palatin. Michael A. Perelman, Ph.D., of the New …

Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal Read More »